Abstract:Aim: To observe the therapeutic effects of salmon calcitonin, which can directively inhibit bone absorption, adjust the activity and number of osteoblasts, and accelerate osteogenesis, on the bone metabolism, fracture healing and low back pain in elderly patients with osteoporotic vertebral fracture. Methods: 1A total of 138 elderly patients with osteoporotic vertebral fracture, who were selected from the Department of Orthopaedics, Renmin Hospital of Wuhan University between June 2000 and June 2003, were randomly divided into two groups: control group (n=65) and salmon calcitonin group (n=73). 2 All the patients lay on the bed with a soft pillow at lower back or upper back, and assisted by oral mid-patent medicine, besides, those in the salmon calcitonin group were treated by intramuscular injection of Miacalcic, once a day for a month continuously, they also took calcium 600 mg per day. 3 Before treatment and 1 month after treatment, blood osteocalcin was determined with radioimmunoassay, the second urine after get-up in the morning was collected, urinary calcium was detected with the azo three arsine method, urinary hydroxyproline with chemiluminoimmunoassay, urinary creatinine with the basic bitter acid method, and the urinary calcium/urinary creatinine ratio and urinary hydroxyproline/urinary creatinine ratio were calculated. 4 The spinogram was reexamined at 4, 6 and 8 weeks after treatment to investigate the condition of fracture healing. 5 The patients were followed up for 12 months by means of reexamination, the fracture healing and low back pain were observed. 6 The difference before and after medication in the same group was compared with the paired t test. Results: Of the 138 patients with osteoporosis, 3 cases stopped the treatment at about 1 week after medication because of the occurrence of facial flush, headache, nausea, emesis and itch of skin after intramuscular injection of Miacalcic, and finally 135 cases were involved in the analysis of results. 1 In the salmon calcitonin group at 1 month after treatment, the blood osteocalcin was obviously higher than that before treatment [(9.43±4.75), (7.41±3.03) μg/L, P< 0.01], urinary hydroxyproline/urinary creatinine ratio was obviously lower than that before treatment [(2.15±0.96), (3.32±0.96) mg/mmol, P < 0.01]. 2 The reexamination of spinogram at 4, 6 and 8 weeks after treatment indicated that the healing rate of fracture was 99% in the salmon calcitonin group and 86% in the control group. The fracture healed in 9 cases at 8 weeks after treatment in the control group. 3 The low back pain disappeared at 2 weeks after treatment in 43 cases and 8 cases respectively in the salmon calcitonin group and control group, that disappeared at 1 month after medication in 19 cases and 29 cases respectively in the salmon calcitonin group and control group. Ten cases in the control group still had lumbag at 1 year after the healing of fracture. Conclusion: Salmon calcitonin can inhibit the bone metabolism and bone absorption of patients with osteoporosis. Salmon calcitonin can accelerate the healing of osteoporotic vertebral fraction, and rapidly improve the symptoms of low back pain.

Study of the clinical application of salmon calcitonin in the prevention of aseptic loosening of the prosthesis after artificial femoral head replacement

Efficacy and safety of Miacalcic ( salmon calcitonin ) in osteoporotic fracture patients: A 12 weeks,open-label,multicenter,observational study

Prevention and Treatment of the Aseptic Loosening of Prosthesis for the Rabbits of Osteoporosis by the Salmon Calcitonin:An Experimental Study

STUDY ON THE EFFECT OF ARTIFICIAL HIP JOINT REPLACEMENT ON BLOOD VESSEL CECs, EPCs AND SERUM OSTEOCALCIN OF PATIENTS WITH TRAUMATIC OSTEONECROSIS OF THE FEMORAL HEAD

Comparative Study of the Impact of Alendronate Sodium and Salmon Calcitonin on Bone-Prosthesis Osseointegration in Osteoporotic Bone

Interventional effects of salmon calcitonin on the bone metabolism, fracture healing and low back pain in elderly patients with osteoporotic vertebral fracture

Application of calcitonin for the treatment of unstable intertrochanteric fractures in elderly patients

Analysis the effect of salmon calcitonin combined with azole phosphonic acid in the treatment of osteoporosis in elderly men

Effects of salmon calcitonin treatment on serum and synovial fluid bone formation and resorption markers in osteoporosis patients

ANALGESIC OUTCOME OF SALMON CALCITONIN AFTER TOTAL KNEE ARTHROPLASTY FOR THE ELDERLY PATIENTS WITH OSTEOPOROSIS

Effects of salmon calcitonin on fracture healing in ovariectomized rats.

The effect of salmon calcitonin on bone mineral density and bone BALP,CICP,CTX-I expression in elderly patients with osteoporotic fracture

Effects of Sequential Treatment with Intermittent Parathyroid Hormone and Zoledronic Acid on Particle-Induced Implant Loosening: Evidence from a Rat Model

Treatment on osteopenia of maintenance hemodialysis patients with salmon calcitonin

Intermittent Administration of Parathyroid Hormone [1-34] Prevents Particle-Induced Periprosthetic Osteolysis in a Rat Model.

Effect of Systemic Calcitonin Delivery with and Without Adjunct Local Platelet-rich Fibrin Therapy on Osseointegration in Ovariectomized Osteoporotic Rabbits: A Scanning Electron Microscopy-based Study

In vivo assessment of bone repair by an injectable nanocomposite scaffold for local co-delivery of autologous platelet-rich plasma and calcitonin in a rat model

Effects of Local and Systemic Alendronate Delivery on Wear Debris-Induced Osteolysis in Vivo

Effectiveness of combined salmon calcitonin and aspirin therapy for osteoporosis in ovariectomized rats

The Effects of Calcitonin Treatment on Bone Quality in Patients Withosteoporosis

Clinical observiation on calcitonin in management of osteoporosis